Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in patients with newly diagnosed prostate cancer referred to androgen‐deprivation therapy

Autor: Simon Buus, Robert Zachariae, Cecilie R. Buskbjerg, S. M. Hadi Hosseini, L. Haldbo-Classen, Claus Højbjerg Gravholt, Ali Amidi
Rok vydání: 2020
Předmět:
Male
Risk
neuropsychological tests
Oncology
Apolipoprotein E
Cancer Research
medicine.medical_specialty
Genotype
Neuropsychological Tests
Catechol O-Methyltransferase
prostatic neoplasms
Androgen deprivation therapy
03 medical and health sciences
Prostate cancer
Apolipoproteins E
0302 clinical medicine
cognitive dysfunction
Internal medicine
medicine
Humans
Cognitive Dysfunction
Testosterone
Patient Reported Outcome Measures
Prospective Studies
030212 general & internal medicine
Effects of sleep deprivation on cognitive performance
brain-derived neurotrophic factor (BDNF)
Aged
apolipoprotein ε (APOE)
medicine.diagnostic_test
business.industry
Brain-Derived Neurotrophic Factor
connectome
Neuropsychology
Brain
Prostatic Neoplasms
Cancer
Androgen Antagonists
Neuropsychological test
medicine.disease
catechol-O-methyltransferase (COMT)
Diffusion Magnetic Resonance Imaging
Case-Control Studies
030220 oncology & carcinogenesis
testosterone
business
Blood sampling
Zdroj: R. Buskbjerg, C, Zachariae, R, Buus, S, H. Gravholt, C, Haldbo-Classen, L, Hosseini, S M H & Amidi, A 2021, ' Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in patients with newly diagnosed prostate cancer referred to androgen-deprivation therapy ', Cancer, vol. 127, no. 9, pp. 1495-1506 . https://doi.org/10.1002/cncr.33387
ISSN: 1097-0142
0008-543X
Popis: Background: Evidence suggests that patients with prostate cancer (PCPs) receiving androgen-deprivation therapy (ADT) are at risk for cognitive impairment. Research with other populations with cancer indicates that cognitive impairment may also occur before systemic treatment. The authors assessed cognitive impairment in untreated PCPs referred to ADT and explored associations with structural brain networks, endocrine status, and selected genotypes. Methods: Forty untreated PCPs and 27 healthy controls (HCs) who completed a questionnaire package underwent neuropsychological testing, magnetic resonance imaging, and blood sampling. Cognitive impairment was defined as a z score ≤−2 on 1 neuropsychological test or ≤−1.5 on 2 neuropsychological tests. Structural brain networks were investigated using diffusion-weighted imaging and graph theory. Associations of cognitive performance with patient-reported outcome measures (PROMs), brain networks, testosterone levels, and genotypes (apolipoprotein ε [APOE], catechol-O-methyltransferase [COMT], and brain-derived neurotrophic factor [BDNF]) were explored. Results: PCPs performed poorer than HCs on 7 of 15 neuropsychological tests and exhibited a higher frequency of cognitive impairment (57.5% vs 22.2%; P ≤.01 to.03). All neuropsychological outcomes were associated with ≥1 PROM (P ≤.01 to.04). Compared with the HC group, the PCP group exhibited altered global network organization as well as disrupted regional network characteristics in frontal and temporal regions (P
Databáze: OpenAIRE
Externí odkaz: